Lifrange E, Colin C
Service de Sénologie, CHU Sart-Tilman, 4000 Liège, Belgique.
J Gynecol Obstet Biol Reprod (Paris). 2000 May;29(3):285-7.
Currently, 30% of the breast biopsies are performed for patients with nonpalpable lesions. The surgical management of these lesions had to evolve to a better three-dimensional targeting and a reduction of the tissue traumatism. The ABBI procedure allows the percutaneous one bloc excision of suspicious mammographically detected lesions with a diameter of less than 2cm. We prospectively evaluated this procedure as a therapeutic tool. Of the 10 malignant lesions with a pathologic size <10mm, 9 (90%) were completely resected with the ABBI device (no residual disease at re-excision of the biopsy site). The results of this preliminary study suggest a potential therapeutic role of the ABBI procedure in the therapeutic arsenal against mammary lesions.
目前，30%的乳腺活检是针对不可触及病变的患者进行的。这些病变的外科治疗方式必须发展为更好的三维靶向定位，并减少组织创伤。ABBI手术可经皮一次性整块切除乳腺钼靶检查发现的直径小于2厘米的可疑病变。我们前瞻性地评估了该手术作为一种治疗手段的效果。在10个病理大小<10毫米的恶性病变中，9个（90%）通过ABBI设备被完全切除（活检部位再次切除时无残留病灶）。这项初步研究的结果表明，ABBI手术在针对乳腺病变的治疗手段中具有潜在的治疗作用。
